Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Bullboard (TSXV:XRTX)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by StockHawk1on Mar 20, 2024 6:53pm

XRTX.v Unveils 2023 Milestones and 2024 Objectives

Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly concerning its lead program aimed at treating a kidney disease called ...more  
58
Post by Betteryear2on Mar 19, 2024 10:07pm

XORTX Highlights Achievements of 2023

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical ...more  
66
Post by KOkidneydiseaseon Mar 19, 2024 1:12pm

use Bluestar BioAdvisors est. net sales to calc a CF NPV

XRx-008 Program Highlights – Independent Commercial Assessment In support of ongoing pharmaceutical partnership discussions, XORTX initiated an independent commercial assessment of the XRx-008 ...more  
53
Post by waves1on Mar 15, 2024 4:58pm

New Patent for Treatment of Chronic Kidney Disease Submitted

Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD.   XRTX is continuing to scale up its supply and to conduct pre-launch activities in prep for a ...more  
62
Post by StockHawk1on Mar 12, 2024 7:53pm

Health Tech: Breakthroughs in Polycystic Kidney Disease and

With a primary focus on polycystic kidney disease and diabetic kidney disease, XORTX Therapeutics (XRTX.v XRTX) is advancing clinical trials for potential groundbreaking therapies that could ...more  
79
Post by waves1on Mar 08, 2024 5:30pm

$14/share Price Target from Alliance Global Partners

New on my Radar: XORTX Therapeutics (NASDAQ/TSXV: XRTX) - $14/share Price Target from Alliance Global Partners   In developing Innovative therapies to improve the quality of life of patients ...more  
97
Post by Iseneschalon Mar 07, 2024 10:26am

XRTX ....Halted on NASDAQ (LUDP) seriously !!!!

No volume (as usual) .....and minimal Price Action Whi in the fack calls the shots ???? Unreal !
44
Comment by KOkidneydiseaseon Mar 06, 2024 2:59pm

RE:XRTX....sure does beat "The Bank Rates" ....LoL

high of the year was $10.62, so my guess is we'll easily surpass that price! We have great momentum.  The initial share price after adjustments is around $43.00 and we are easily a much less ...more  
49
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next